Company CVAbout Dishman Carbogen Amcis Ltd 
Dishman Carbogen Amcis Ltd
Small Cap
Pharmaceuticals & Drugs
Dishman Carbogen Amcis Limited was formerly incorporated as Carbogen Amcis (India) Limited on July 17, 2007. The Company name later on was changed to Dishman Carbogen Amcis Limited effective from 27 March 2017. The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
Company Coordinates
Company Details
Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 31.36 Cr
Number of Shares
15.68 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
24-Jul-2020
15.68
31.36
-80000
2
Buy Back of Shares
31-Mar-2020
15.69
31.37
-4531177
2
Buy Back of Shares
21-Sep-2017
16.14
32.28
161394272
2
Amalgamation
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 6 Schemes (1.22%)
FIIs
Held by 59 FIIs (8.75%)
Promoter with highest holding
Adimans Technologies Llp (59.32%)
Highest Public shareholder
Mukul Mahavir Agrawal (5.5%)
Individual Investors Holdings
26.22%
Board of Directors
Management
Designation
Remuneration
Janmejay R Vyas
Chairman (Non-Executive)
0
Deohooti J Vyas
Whole-time Director
1.2 cr
Arpit J Vyas
Managing Director & CFO
0
Sanjay S Majmudar
Independent Director
19.2 lacs
Ashok C Gandhi
Independent Director
14.6 lacs
Subir Kumar Das
Independent Director
13.8 lacs
Rajendra S Shah
Independent Director
9.4 lacs
Shrima Dave
Company Sec. & Compli. Officer
0
Maitri K Mehta
Independent Director
8.4 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Others
0.19
0.03%
Others
Others
Stock DNARevenue and Profits:
Net Sales:
682 Cr
(Quarterly Results - Dec 2024)
Net Profit:
5 Cr
Pharmaceuticals & Drugs
INR 3,198 Cr (Small Cap)
NA (Loss Making)
33
0.00%
0.36
-2.84%
0.52
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
